Publication date: Dec 21, 2024
Background: Coronavirus Disease 2019 (COVID-19), triggered by SARS-CoV-2, has represented a global pandemic associated with an elevated rate of mortality, mainly among older individuals. The extensive pulmonary involvement by the viral infection might have precipitated pre-existing chronic conditions in this vulnerable population, including heart failure (HF). Materials and Methods: The aim of this retrospective, observational study was to assess the impact of COVID-19 in patients with a prior diagnosis of HF referred to the Emergency Department of the Agostino Gemelli University Hospital between March 2020 and January 2023. A total of 886 HF patients (444 men and 442 women, mean age of 80 +/- 10 years) were identified. Patients were matched in a 1:1 ratio by gender, age, number of comorbidities (excluding HF), and vaccination status, using a propensity score matching (PSM) procedure. We compared the outcomes of 189 patients with a concomitant diagnosis of HF with those of 189 matched controls without HF. Results: Among patients with HF, there was a significantly higher prevalence of valvular disease (p = 0. 004), atrial fibrillation (p = 0. 003), use of anticoagulants (p = 0. 001), chronic obstructive pulmonary diseases (p = 0. 03), and chronic kidney disease (p = 0. 001). In contrast, hypertension was more prevalent among controls than HF patients (p = 0. 04). In addition, controls exhibited higher lymphocytes counts and a higher PaO/FiO ratio compared to HF patients. During hospitalization, patients with HF were more frequently treated with high-flow nasal cannulas (p = 0. 01), required more frequent admission to an intensive care unit (ICU) (p = 0. 04), and showed a significantly higher mortality rate (p 0. 0001) than controls. Conclusions: HF is an independent risk factor for ICU admission and death in COVID-19 patients.
Open Access PDF
Concepts | Keywords |
---|---|
Coronavirus | COVID-19 |
Hospitalization | heart failure |
Italian | sex differences |
Kidney | vaccination |
Women |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Heart Failure |
disease | MESH | COVID-19 |
disease | MESH | viral infection |
disease | MESH | chronic conditions |
disease | MESH | Emergency |
disease | MESH | atrial fibrillation |
disease | MESH | chronic obstructive pulmonary diseases |
disease | MESH | chronic kidney disease |
disease | MESH | hypertension |
disease | MESH | death |
drug | DRUGBANK | Ribostamycin |
drug | DRUGBANK | Coenzyme M |
disease | MESH | syndrome |
disease | MESH | neoplasms |
disease | MESH | obesity |
disease | IDO | blood |
drug | DRUGBANK | Trihexyphenidyl |
disease | IDO | history |
drug | DRUGBANK | Etoperidone |
drug | DRUGBANK | Trestolone |
disease | MESH | pulmonary embolism |
drug | DRUGBANK | Oxygen |
disease | MESH | stenosis |
disease | MESH | inflammatory bowel diseases |
disease | MESH | neurological disorders |
drug | DRUGBANK | Fibrinogen Human |
drug | DRUGBANK | Urea |
drug | DRUGBANK | Nitrogen |
drug | DRUGBANK | Tocilizumab |
disease | MESH | Comorbidity |